

Contents

1	Introduction	
1.1	Types of Models	3
1.1.1	Compartmental modelling	3
1.2	Partial Volume Effect	5
1.3	Aims	6
1.4	Thesis Outline	6
2	Quantification of [¹⁸F]DPA-714 binding	
2.1	Introduction	13
2.2	Materials and methods	13
2.2.1	Subjects	13
2.2.2	Synthesis of [¹⁸ F]DPA-714	14
2.2.3	PET scanning protocol and image reconstruction	14
2.2.4	Data analysis	15
2.2.5	Statistical analysis	16
2.3	Results	16
2.3.1	Demographic data	16
2.3.2	Plasma input analysis	17
2.3.3	Validation of SRTM	17
2.3.4	Preliminary assessment of potential group differences	20
2.4	Discussion	20
2.5	Conclusions	22
3	Parametric imaging of [¹⁸F]DPA-714 binding	
3.1	Introduction	31
3.2	Materials and methods	31
3.2.1	Subjects	31
3.2.2	Scanning protocol	32
3.2.3	Data analysis	32
3.2.3.1	Parametric methods	32
3.2.3.2	Statistical Parametric Mapping (SPM)	33
3.2.4	Parametric images	34
3.2.5	Statistical parametric mapping	37
3.3	Discussion	37
3.4	Conclusion	39

4	Quantification of [¹¹C]GMOM	
4.1	Introduction	47
4.2	Materials and methods	48
4.2.1	Subjects	48
4.2.2	Radiochemistry	48
4.2.3	Positron Emission Tomography	48
4.2.3.1	S-ketamine challenge	48
4.2.3.2	Input function	49
4.2.3.3	Regions of Interest	49
4.2.3.4	Kinetic Modeling	50
4.2.3.5	Statistics	50
4.3	Results	50
4.3.1	Input function and plasma metabolite analysis	50
4.3.2	S-ketamine	50
4.3.3	Region of interest data analysis	52
4.3.4	Kinetic modeling	52
4.4	Discussion	56
4.5	Conclusion	59
5	Preclinical evaluation of [¹⁸F]PK-209	
5.1	Introduction	71
5.2	Materials and Methods	72
5.2.1	Selectivity profile of PK-209	72
5.2.2	Radiotracer preparation	72
5.2.3	Subjects, anaesthesia and treatment	73
5.2.4	Image acquisition	74
5.2.5	Blood sampling and metabolite analysis	75
5.2.6	Image processing	75
5.2.7	Data analysis and statistics	76
5.3	Results	76
5.3.1	<i>In vitro</i> pharmacological selectivity profile of PK-209	76
5.3.2	Physiological response to anaesthesia	76
5.3.3	Metabolism of [¹⁸ F]PK-209	77
5.3.4	Pharmacokinetics of [¹⁸ F]PK-209	78
5.3.5	Regional distribution of radioactivity and time-activity curves (TACs), at baseline and after MK-801 treatment	79
5.3.6	Effect of MK-801 administration on the V _T of [¹⁸ F]PK-209	79
5.4	Discussion	79
5.5	Conclusions	85
6	Model selection criteria	
6.1	Introduction	95
6.2	Materials and methods	95
6.3	Results	97
6.4	Discussion	101

7	Partial volume correction	
7.1	Introduction	107
7.2	Material and Methods	108
7.2.1	Iterative deconvolution methods (IDM)	108
7.2.2	HighY constrained back-PRojection (HYPR)	108
7.2.3	Parameter estimation	108
7.2.4	Order of Implementation	109
7.2.5	Phantom studies	109
7.2.6	Clinical studies	109
7.3	Results	110
7.3.1	Parameter optimisation	110
7.3.2	Order of implementation	111
7.3.3	Clinical studies	112
7.4	Discussion	113
7.5	Conclusion	120
8	Summary	
8.1	Future perspectives	129
	Publications	135
	Acknowledgements	137
	Curriculum Vitae	141

